Antibiotics for the newborn

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue SUPPL. 3, 2009, Pages 46-49

  Chirico, Gaetano ^a   Barbieri, Fabiana ^a   Chirico, Claudia ^a  

^a Spedali Civili ^*  (Italy)

Author keywords

Antibiotics; Infection; Newborn; Preterm infant

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CALCIUM; CARBAPENEM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BIRTH WEIGHT; CHOLESTASIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GASTROINTESTINAL MOTILITY DISORDER; GESTATIONAL AGE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEART ARRHYTHMIA; HUMAN; IMMATURITY; INFECTION SENSITIVITY; INTRAUTERINE GROWTH RETARDATION; KIDNEY FUNCTION; LIVER FUNCTION; LUNG DYSPLASIA; NEUROLOGICAL COMPLICATION; NEWBORN MORTALITY; NEWBORN PERIOD; NEWBORN SEPSIS; PARAMETER; PARENTERAL NUTRITION; PREMATURITY; PRIORITY JOURNAL; PYLORUS STENOSIS; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTION CONTROL; INTENSIVE CARE, NEONATAL; MICROBIAL SENSITIVITY TESTS;

EID: 70449441394     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050903192192     Document Type: Review

References (23)

1. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006;117:1979-1987.
2. Palazzi DR, Klein JO, Baker CJ. Bacterial sepsis and meningitis. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant, 6th ed. Philadelphia: Elsevier Saunders Company; 2006. pp 248-295.
3. Chirico G. Development of the immune system in neonates. J Arab Neonatal Forum 2005;2:5-11.
4. Fanos V, Cuzzolin L, Atzei A, Testa M. Antibiotics and antifungals in neonatal intensive care units: a review. J Chemother 2007;19:5-20.
5. de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005;10:185-194.
6. Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant, 6th ed. Philadelphia: W.B. Saunders Company; 2006.
7. Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006;(1):CD005091.
8. Nestaas E, Bangstad HJ, Sandvik L, Wathne KO. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 2005;90:F294-F300.
9. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117:67-74.
10. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr; National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006;118:717-722.
11. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92.
12. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, Ambalavanan N, Benjamin DK Jr; NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009;123:58-66.
13. Sehgal R, Gaind R, Chellani H, Agarwal P. Extendedspectrum b lactamase-producing gram-negative bacteria: clinical profile and outcome in a neonatal intensive care unit. Ann Trop Paediatr 2007;27:45-54.
14. Kumar S, Kohlhoff S, Valencia G, Hammerschlag MR, Sharma R. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents 2007;29:740-741.
15. Hufnagel M, Liese C, Loescher C, Kunze M, Proempeler H, Berner R, Krueger M. Enterococcal colonization of infants in a neonatal intensive care unit: associated predictors, risk factors and seasonal patterns. BMC Infect Dis 2007;7: 107.
16. Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, Pidoux O, Badr M, Picaud JC. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed 2008;93:F418-F421.
17. Rubin LG, Sánchez PJ, Siegel J, Levine G, Saiman L, Jarvis WR; Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics 2002;110:e42.
18. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or - resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256-2259.
19. Ng PC. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants. Neonatology 2009;95:97-104.
20. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, Eydelman R, Strande L, Leone P, Rahman I. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62:483-488.
21. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007;8:41.
22. Isaacs D. Unnatural selection: reducing antibiotic resistance in neonatal units. Arch Dis Child Fetal Neonatal Ed 2006;91:F72-F74.
23. Alm B, Erdes L, Möllborg P, Pettersson R, Norvenius SG, Aberg N, Wennergren G. Neonatal antibiotic treatment is a risk factor for early wheezing. Pediatrics 2008;121:697-702.